Cargando…

Reinfection with SARS-CoV-2 and Waning Humoral Immunity: A Case Report

Recovery from COVID-19 is associated with production of anti-SARS-CoV-2 antibodies, but it is uncertain whether these confer immunity. We describe viral RNA shedding duration in hospitalized patients and identify patients with recurrent shedding. We sequenced viruses from two distinct episodes of sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldman, Jason D., Wang, Kai, Röltgen, Katharina, Nielsen, Sandra C. A., Roach, Jared C., Naccache, Samia N., Yang, Fan, Wirz, Oliver F., Yost, Kathryn E., Lee, Ji-Yeun, Chun, Kelly, Wrin, Terri, Petropoulos, Christos J., Lee, Inyoul, Fallen, Shannon, Manner, Paula M., Wallick, Julie A., Algren, Heather A., Murray, Kim M., Hadlock, Jennifer, Chen, Daniel, Dai, Chengzhen L., Yuan, Dan, Su, Yapeng, Jeharajah, Joshua, Berrington, William R., Pappas, George P., Nyatsatsang, Sonam T., Greninger, Alexander L., Satpathy, Ansuman T., Pauk, John S., Boyd, Scott D., Heath, James R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861578/
https://www.ncbi.nlm.nih.gov/pubmed/36679852
http://dx.doi.org/10.3390/vaccines11010005
Descripción
Sumario:Recovery from COVID-19 is associated with production of anti-SARS-CoV-2 antibodies, but it is uncertain whether these confer immunity. We describe viral RNA shedding duration in hospitalized patients and identify patients with recurrent shedding. We sequenced viruses from two distinct episodes of symptomatic COVID-19 separated by 144 days in a single patient, to conclusively describe reinfection with a different strain harboring the spike variant D614G. This case of reinfection was one of the first cases of reinfection reported in 2020. With antibody, B cell and T cell analytics, we show correlates of adaptive immunity at reinfection, including a differential response in neutralizing antibodies to a D614G pseudovirus. Finally, we discuss implications for vaccine programs and begin to define benchmarks for protection against reinfection from SARS-CoV-2.